Syntara (ASX:SNT) has recently completed an $8m Placement of new shares to new and existing investors, and in conjunction, announced a Share Purchase Plan (SPP) to raise a further $2m from existing eligible shareholders.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The attached video discusses the SPP and why Syntara represents a compelling investment proposition, approaching a period of frequent newsflow across its portfolio of programs through the rest of CY26.
Highlights
- The $8M Placement saw Syntara’s largest specialist healthcare investor increase its stake in the company, a strong vote of confidence in Syntara’s strategy.
- Syntara’s lead asset, amsulostat, has just received a positive review from the FDA for its late-stage clinical development plan, with a Phase 2b study in myelofibrosis to commence.
- Period of substantial newsflow pending:
- SNT4728 Phase 2 data in Parkinsons expected later this quarter.
- Skin scarring program with two studies ongoing to report data later in the year.
- Two further studies of amsulostat in myelodysplastic syndrome, due to have data read-outs before the end of the year.
- A comparatively modest valuation despite the various “shots on goal.”
Join the discussion: See what HotCopper users are saying about Syntara Ltd and be part of the conversations that move the markets.
Disclaimer: This content has been prepared as part of a partnership with Syntara Ltd and is intended for informational purposes only.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.